

Beyond Checkpoint Blockade to Defeat Cancer


Company Overview

A*t Therapeutics Inc. is a newly established biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in metastatic solid tumors and rare hematological malignancies. A*t Therapeutics focuses on T cells and Natural Killer (NK) cells, and is leveraging multiple advanced technologies, including human Ig transgenic (Tg) rodent derived fully human antibodies, NK cell engager bispecific antibodies, and multi-functional tri-specific antibodies. Our initial product portfolio focuses on both hematological malignancies such as cutaneous lymphoma and solid tumors including triple negative breast cancer, ovarian, colon, kidney, renal and pancreatic cancers.

Company Highlights

- Multiple Hematological & Solid Tumor Therapeutic Programs for single and/or combo therapy with checkpoint blockade, expected to file patents starting 2021H1
- Proprietary Global Leading Antibody Discovery Technologies
- Two state-of-art bispecific and tri-specific antibody technology platforms to unlock the full power of immune cells
- World Class Partnership with human Ig Tg rodent companies
- Experienced Industrial Team in therapeutic antibody drug R&D

A Diversified Pipeline with multiple approaches to unlock the full power of immune cells



World Class Partnerships



Collaboration with acknowledged pioneer and leader in 2nd generation human Ig Tg OmniAb and RenMab technology to expediate isolation of naturally optimized fully human antibodies.

State-of-Art Multi-Specific Antibodies

Bispecific NK cell engagers targeting a specific tumor antigen while leveraging the power of the innate immune system (NK Cells); Tri-specific antibodies blocks PD-L1 interactions with PD-1, sequesters inhibitory cytokines to unlock the inhibition of multiple immune cells, e.g. T cells, NK cells, dendritic cells (DCs) and macrophages, and attracts and proliferate professional cytotoxic tumor killing T cells and NK cells.

Broad Biopharma Experience

